PubMed Health⌕ Search

Biomedical subjects

Joanna Wierzbowska

Publications and source records attributed to Joanna Wierzbowska.

9 recordsLinked to original sources
PubMed2005

[Subconjuctival application of 5-fluorouracil (5-FU) following surgical treatment of glaucoma with deep sclerectomy--indications, complications and initial evaluation of effectiveness].

PURPOSE: 5-FU is an antimetabolite which increases efficacy of deep sclerectomy by inhibiting subconjuctival fibrosis and fibroblast proliferation. The objective of the study was to analyze glaucoma patients who had undergone sclerectomy and in a post-surgery period required subconjuctival 5-FU injections. MATERIAL AND METHODS: Out of 120 patients who had undergone deep sclerectomy between January through November 2004, 17 were included in the study since they required subconjuctival 5-FU injections in a post-operative period. The analysis comprised of: (1) indications for antimetabolite administration; (2) time that elapsed from the surgery to the first antimetabolite administration; (3) mean dosage; (4) complications observed; and (5) initial evaluation of the treatment. RESULTS: In 13 patients (76.4%), the indication for 5-FU application was persistent intraocular pressure exceeding 15 mmHg; in one patient (5.8%), the 5-FU treatment was started due to an abrupt increase of the pressure from hypotony; in 6 subjects (35.2%), it was the thickening and vascular dilatation in the filtering bleb; in one subject (5.8%) encapsulated filtering bleb. Mean time of administering 5-FU was between the 2nd and 3rd week following surgery. Mean number of injections applied was 3.7 (18.5 mg 5-FU). The following complications were encountered: corneal superficial punctuate keratopathy (6 subjects), choroidal detachment (1 person), irregular astigmatism (1 person). In most cases IOP was well controlled by the end of the follow-up period (< or = 15 mmHg). CONCLUSIONS: 5-FU is safe and does not increase the perioperative risk, and has turned out to be effective in most cases of increased scarring in the filtering bleb site.

Aged↗
PubMed2005

[The present role of prostaglandin analogues in the medical treatment of glaucoma].

Therapy with prostaglandin analogues (PGA), a novel class of intraocular-lowering medications, represents a safe and very effective pharmacologic method of treating patients with glaucoma and ocular hypertension. The convince dosing regimen, once-daily, higher efficacy and higher systemic safety profile seen with PGA compared with beta-blockers caused that these agents have been approved by regulatory bodies for both the first-line and adjunctive therapy. Short, retrospective analysis of the medical treatment of glaucoma in the Ophthalmology Clinic of Military Health Service Institute in Warsaw, in 2003-2004, was presented.

Adrenergic beta-Antagonists↗
PubMed2004

[Theoretical and clinical aspects of the use of prostaglandins in glaucoma therapy].

In the first part of the article the main information and recent research on the uveoscleral outflow pathway, including its morphology and physiology were presented. The structure of extracellular matrix of ciliary muscle and the changes of it, that are induced by prostaglandins, resulting in decreasing intraocular pressure were emphasized. In the second part biochemical characteristics of prostaglandin analogues, using nowadays were presented. Their efficacy in reducing intraocular pressure and safety profile were described.

Amides↗
PubMed2004

[Optic nerve damage in multiple sclerosis patients].

PURPOSE: The aim of the work was to catch the type of damage of optic nerve in the group of patients with multiple sclerosis. MATERIAL AND METHODS: The examinations were held on 77 eyes of 40 patients with multiple sclerosis. Among them 11 patients had previous optic neuritis, 29 have not problems with vision. The examination was conducted by CSV-1000 contrast test depict on contrast sensitivity function and anomaloscopy AN-69 appointing coefficient eta and threshold of red, green and blue hue. RESULTS: As a result, two groups of selective damage and one of non-selective eyes were obtained. In 5 eyes (6.5% examined group eyes) were selective damage of contrast sensitivity in 18 cdg connected with increased threshold for blue hue. The second group of 4 eyes (5.2% examined eyes) were characteristic by damage of contrast sensitivity in 12 cdg and increased threshold of red hue on the border of probable protanomaly. The rest 60 eyes (77.9% the examined group) were non-selective in psychophysical tests. In the eyes of that group were stated non-specific dyschromatopsy connected with equal decrease of contrast sensitivity function, with the tendency to serious changes in high spatial frequency. CONCLUSIONS: Psychophysical tests enable early diagnosis and monitoring of optic nerve damage in multiple sclerosis patients.

Adult↗
PubMed2004

[A multicentre, observative, non-invasive study of the tolerance of NYOLOL gel 0,1% in ocular hypertensive patients].

PURPOSE: To evaluate the safety and efficacy of Nyolol Gel 0,1%/Novartis vs. regular timolol formulation (Ofterisin 0,5%) in ocular hypertensive patients. MATERIAL AND METHODS: A comparative, multicentred non-invasive, 16-weeks study. 192 glaucoma or ocular hypertensive patients were randomized into 2 groups: patients receiving regular timolol treatment (group I) and patients treated with timolol gel formulation. After 8 weeks of assigned treatment subjects from group I were switched to Nyolol gel and the subjects from group B - to regular timolol respectively. Intraocular pressure (IOP), objective and subjective tolerance of treatment were evaluated. RESULTS: There were no differences between groups as far as level of IOP was concerned. The incidence of ocular adverse events was higher when patients were switched to timolol aqueous eye drops. Subjective local tolerance of timolol gel formulation was better than conventional eye drops. CONCLUSIONS: Timolol 0,1% gel formulation with a once daily application provides an IOP reduction equivalent to timolol 0,5% solution given twice a day. Local tolerability and safety of gel formulation is better than aqueous solution, both in the patient's and physician's opinions.

Adrenergic beta-Antagonists↗
PubMed2003

[Influence of topically applied iodides on urinary iodine excretion and thyroid function].

PURPOSE: The present study was undertaken, to evaluate whether ophthalmic drug, containing iodine applied to conjunctival sac might result in a significant increase of urine iodine excretion and thus might be indirectly associated with the risk of iodine-induced hyperthyroidism. The aim of the study was to examine the occurrence of biochemically relevant changes in urine iodine excretion and in thyroid function after topical administration of ophthalmic drug containing iodine. MATERIAL AND METHODS: In the study twenty-two patients without a history of thyroid disease were examined. The Vitreolent (Ciba Vision) was applied topically to conjunctival sac four times a day for one month. The urinary iodine excretion, using "Rapid Urinary Iodine Test" (Merck KgaA) and parameters of thyroid function (TSH, FT3, FT4) were measured before starting and after therapy. RESULTS: The data showed, that was a significant increase in urinary iodine excretion at the end of therapy; as far as thyroid function was concerned, neither changes in level of TSH nor thyroid hormones were observed.

Administration, Topical↗
PubMed2002

[Pathogenesis and management of Grave's ophthalmopathy].

The most recent hypothesis on pathogenesis of Graves' Ophthalmopathy (GO) and short characteristics of the disease was presented. Emphasis was placed on the necessity of coordinated treatment of the thyroid dysfunction and ophthalmopathy. Management of hyperthyroidism and Graves' ophthalmopathy, including the latest methods was described.

Graves Disease↗